PARIS, Feb 11 (APM) - A collection of healthcare associations has urged France’s drugs pricing and reimbursement committee CEPS to take into account total R&D costs, as well as manufacturing and distribution expenses, when it assesses a new treatment.
CISS - a health collective of around 30 French associations - said CEPS should take into account cost of “R&D, production and marketing as well as the cost of post-marketing authorisation monitoring of the drug (as) justified by the holder of the drug’s marketing authorisation,” when considering drug pricing.
CISS made the plea in a statement on Tuesday as part of its proposed 31 amendments to France’s new health bill due to be examined in parliament in early April.
In its contribution, CISS regrets that the first title of the proposed law, dedicated to prevention and health promotion “does not propose any generic tool for changing the scale of public health action on a daily basis in the territories”. It also regrets there is no measure to enforce a minimal spend by regional health agencies (ARS) on prevention.
It also regrets the absence of measures to establish a legal status for user and patient representatives and proposes the set up of a universal user rights commission.
CISS further recommends including prevention objectives in the tripartite agreements signed among ARS, hospitals and health insurance, to guarantee of a minimum public health financing threshold for the regional health agencies and a legal definition of care denial.
It also suggests modifying from 30% to 20% the cap for participation by the insured people (copayment) for medical consultations, and integrating the state medical assistance (AME) mechanism with universal healthcare coverage (CMU) so as to generate economies of scale and facilitate healthcare access for foreigners who do not yet have the required documents.
Shortly before its adoption in a cabinet meeting in October 2014, CISS had already expressed disappointment over various aspects of the text, due to be examined in parliament early in April.
In its statement, the collective repeats its support for provisions “that contribute to reducing obstacles to care access, such as the generalisation of third party payment system,” and those in favour of prevention, health promotion and of accompanying patients, as well as those relating to health democracy.
However, it claims many points in the proposed law remain imperfect and thoroughly criticises Article 47 that re-organises access to health data, on the one hand, and the absence of measures to review the mechanism for setting drug prices, mentioning the episode of new very costly treatments for chronic hepatitis C, on the other.
vg/aki/hlc
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
